ÂÜÀòÂÒÂ×

Yawei Zhang is a seasoned professional in the research field, currently working as a Trial Lead and Medical Monitor at Daiichi Sankyo, Inc. since January 2018. Prior to this role, Zhang served as the Director at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, from July 2007 to December 2017. Zhang holds a Doctor of Medicine (M.D.) degree from Tianjin Medical University and a Master's degree from UNC Chapel Hill.